A Phase 3 interventional study of CTAP101 30 μg capsules and Sugar pill to CTAP101 30 μg capsules in Chronic Kidney Disease, Hyperparathyroidism, Secondary and Vitamin D Deficiency, sponsored by OPKO IP Holdings II, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-13.
Sponsored by OPKO IP Holdings II, Inc. (part of OPKO Health, Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 170 open to participants now, 218 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.
Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 213th largest by enrollment of the 819 interventional ones that give a count, is one of 36 that started in 2012, is one of 147 in phase 3, and was the 261st registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →170 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18–70
Indiana University · Sites in United States
Ages 40–70
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
University of Minnesota · Sites in United States
Ages 30–75
United Therapeutics · Sites in United States
Ages 40–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
988 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 109 · Phase 2 185 · Phase 3 160 · Phase 4 81
First in 1988; this study’s year is marked. 36 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 213 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 72 across the 819 interventional studies, 125 across the 165 observational. Of the 696 that completed or were terminated, 344 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
372 of 988 have an industry lead sponsor. The 10 most frequent:
This study is registered under OPKO IP Holdings II, Inc., one of the names counted as OPKO Health, Inc.. Under that name alone:
OPKO IP Holdings II, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
OPKO Health, Inc. has 9 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
73 of the studies in Renal Insufficiency, Chronic with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03565913Phase 3University of Texas Southwestern Medical CenterPotential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V | 2026-12-01 |
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
Add all 73 to your calendar (.ics) → With an account.
Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of CTAP101 Capsules administered for 26 weeks to treat SHPT in subjects ≥18 years of age with stage 3 or 4 CKD and vitamin D insufficiency. The study will be conducted at approximately 40 sites within the United States (US). Approximately 550 subjects will be screened to randomize approximately 210 eligible subjects, stratified by CKD stage (approximately 105 subjects in each stage) in a 2:1 ratio to receive either CTAP101 Capsules or matching placebo. An Interactive Voice Response System (IVRS) will provide study treatment group assignments using the computer-generated randomization code provided by the IVRS vendor. Subjects will receive an initial daily dose of 1 capsule (CTAP101 Capsules, 30 µg, or matching placebo) for the first 12 weeks. After l2 weeks (visit 8) and per pre-defined criteria, the dose may be increased in a blinded fashion by the IVRS with oversight by an independent medical monitor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 CTAP101 30 μg capsule daily at bedtime for 12 weeks, with a possible increase to 2 CTAP101 30 μg capsules daily at bedtime for study duration, if needed (26 weeks total). Subjects not requiring a dose increase after 12 weeks would receive 1 CTAP101 30 μg capsule and one sugar pill (to CTAP101 30 μg capsule) for weeks 13-26.
Drug: CTAP101 30 μg capsules · Other: Sugar pill to CTAP101 30 μg capsules
1 sugar pill to CTAP101 30 μg capsule daily at bedtime for 12 weeks, with an increase to 2 sugar pills to CTAP101 30 μg capsules daily at bedtime for weeks 13-26.
Other: Sugar pill to CTAP101 30 μg capsules
CTAP101 30 μg capsule taken daily at bedtime.
Also known as: Calcifediol
Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
Also known as: Placebo
Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values
Number of subjects in the intent to treat population attaining a mean decrease in plasma intact parathyroid hormone (iPTH) of ≥30% from pre-treatment baseline in the efficacy assessment phase (EAP), referred to as responders.
Time frame: Approximately 6 months
Number of Participants in the Per Protocol Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values
Number of subjects in the per protocol population attaining a mean decrease in plasma intact parathyroid hormone (iPTH) of ≥30% from pre-treatment baseline in the efficacy assessment phase (EAP), referred to as responders.
Time frame: Approximately 6 months
Subjects in the Intent to Treat Population With Normal Serum Total 25-hydroxyvitamin D
Subjects in the Intent to Treat Population with normal serum total 25-hydroxyvitamin D (\>/= 30 ng/dL)
Time frame: Approximately 6 months
Subjects in the Per Protocol Population With Normal Serum Total 25-hydroxyvitamin D
Subjects in the Per Protocol Population with normal serum total 25-hydroxyvitamin D (\>/= 30 ng/mL)
Time frame: Approximately 6 months
This multicenter study was conducted at 44 investigational sites within the US. Subjects were enrolled and treated from 07 September 2012 through 20 July 2014.
| Milestone | Sugar Pill to CTAP101 30 μg Capsule | CTAP101 30 μg Capsules |
|---|---|---|
| Started | 72 | 141 |
| Entered extension study | 50 | 93 |
| Completed | 62 | 113 |
| Not completed | 10 | 28 |
| Withdrew: Adverse event | 2 | 8 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Protocol violation | 0 | 3 |
| Withdrew: Withdrawal by subject | 2 | 10 |
| Withdrew: Subject noncompliance | 0 | 3 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Administrative reason | 1 | 0 |
| Withdrew: Serum ca >/= 11.0 mg/dl, repeat confirm | 0 | 1 |
Number of subjects in the intent to treat population attaining a mean decrease in plasma intact parathyroid hormone (iPTH) of ≥30% from pre-treatment baseline in the efficacy assessment phase (EAP), referred to as responders.
| participants | Sugar Pill to CTAP101 30 μg Capsule | CTAP101 30 μg Capsules |
|---|---|---|
| Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values | 6 | 46 |
Number of subjects in the per protocol population attaining a mean decrease in plasma intact parathyroid hormone (iPTH) of ≥30% from pre-treatment baseline in the efficacy assessment phase (EAP), referred to as responders.
| participants | Sugar Pill to CTAP101 30 μg Capsule | CTAP101 30 μg Capsules |
|---|---|---|
| Number of Participants in the Per Protocol Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values | 5 | 46 |
Subjects in the Intent to Treat Population with normal serum total 25-hydroxyvitamin D (\>/= 30 ng/dL)
| participants | Sugar Pill to CTAP101 30 μg Capsule | CTAP101 30 μg Capsules |
|---|---|---|
| Subjects in the Intent to Treat Population With Normal Serum Total 25-hydroxyvitamin D | 2 | 113 |
Subjects in the Per Protocol Population with normal serum total 25-hydroxyvitamin D (\>/= 30 ng/mL)
| participants | Sugar Pill to CTAP101 30 μg Capsule | CTAP101 30 μg Capsules |
|---|---|---|
| Subjects in the Per Protocol Population With Normal Serum Total 25-hydroxyvitamin D | 2 | 110 |
Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sugar Pill to CTAP101 30 μg Capsule | — | 12/72 (16.7%) | 37/72 (51.4%) |
| CTAP101 30 μg Capsules | — | 30/141 (21.3%) | 44/141 (31.2%) |
| Event | Sugar Pill to CTAP101 30 μg Capsule | CTAP101 30 μg Capsules |
|---|---|---|
| Cardiac failure congestiveCardiac disorders | 0/72 | 6/141 |
| Blood creatinine increasedInvestigations | 0/72 | 5/141 |
| Chest painGeneral disorders | 2/72 | 2/141 |
| AnaemiaBlood and lymphatic system disorders | 1/72 | 2/141 |
| Atrial fibrillationCardiac disorders | 0/72 | 2/141 |
| SepsisInfections and infestations | 1/72 | 2/141 |
| UrosepsisInfections and infestations | 0/72 | 2/141 |
| Renal failure acuteRenal and urinary disorders | 1/72 | 2/141 |
| HyponatraemiaMetabolism and nutrition disorders | 1/72 | 0/141 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/72 | 0/141 |
| Event | Sugar Pill to CTAP101 30 μg Capsule | CTAP101 30 μg Capsules |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 12/72 | 6/141 |
| Urinary tract infectionInfections and infestations | 10/72 | 7/141 |
| NauseaGastrointestinal disorders | 6/72 | 3/141 |
| Back painMusculoskeletal and connective tissue disorders | 6/72 | 6/141 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/72 | 3/141 |
| VomitingGastrointestinal disorders | 5/72 | 2/141 |
| Oedema peripheralGeneral disorders | 5/72 | 3/141 |
| HypertensionVascular disorders | 5/72 | 9/141 |
| Chest painGeneral disorders | 4/72 | 3/141 |
| Upper respiratory tract infectionInfections and infestations | 4/72 | 4/141 |
Intent to Treat
| Age, Continuous(years) | Sugar Pill to CTAP101 30 μg Capsule | CTAP101 30 μg Capsules | Total |
|---|---|---|---|
| Mean | 64.4 ± 12.74 | 65.1 ± 10.33 | 64.9 ± 11.18 |
| Sex: Female, Male(Participants) | Sugar Pill to CTAP101 30 μg Capsule | CTAP101 30 μg Capsules | Total |
|---|---|---|---|
| Female | 33 | 71 | 104 |
| Male | 39 | 70 | 109 |
| Region of Enrollment(participants) | Sugar Pill to CTAP101 30 μg Capsule | CTAP101 30 μg Capsules | Total |
|---|---|---|---|
| United States | 72 | 141 | 213 |
The record gives a start of Sep 2012, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 2 years 1 month after primary completion. A results delay was requested in Oct 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Modified-release Calcifediol Capsule
Renal Insufficiency, Chronic →